USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 28, 2013.
For the third quarter of 2013, net sales increased by 5.2% to $173.7 million, compared with $165.2 million in the prior-year period. The growth in net sales was driven by increases in both the Company’s Asia Pacific and North America/Europe regions. Net sales for the quarter were negatively impacted by: (i) an estimated $5.9 million due to the worldwide policy changes that the Company implemented at the end of the second quarter of this year, which require customers to purchase products in their home markets; (ii) $4.6 million due to the strategic price discounts that the Company announced at its International Convention in August and earlier this year; and (iii) $2.0 million due to changes in currency exchange rates.
Net earnings for the third quarter decreased by 4.2% to $16.8 million, compared with the prior-year period. This decrease was due primarily to higher Associate Incentives expense, attributable to the enhancements that the Company made to its Associate Compensation Plan at its August 2013 International Convention. Additionally, the effective tax rate for the third quarter was 420 basis points, or $1.0 million, higher than the previous year, due primarily to one-time tax benefits recognized in the third quarter of 2012. Earnings per share for the quarter decreased by 1.7% to $1.16, compared with $1.18 in the third quarter of the prior year. This decrease in earnings per share was attributable to lower net earnings, partially offset by a lower number of diluted shares outstanding from the Company’s share repurchases during the 12 months ended September 29, 2013. Total diluted common shares outstanding as of September 28, 2013 were 14.4 million, compared with 14.9 million as of September 29, 2012.
“During the third quarter, we implemented a number of strategic initiatives at our 2013 International Convention,” said Dave Wentz, the Company’s Chief Executive Officer. “These initiatives, which include price reductions and enhancements to our Associate compensation plan, are intended to drive long-term, sustainable customer growth for USANA. The combination of these initiatives and the worldwide policy changes that we introduced in the second quarter had the meaningful impact that we anticipated on our third-quarter results. Although it is still early, these initiatives have already produced several anticipated positive results, including: (i) an increase of approximately 30% in our worldwide Auto Order sales; (ii) an increase of approximately 40% in the number of weekly commission checks earned by Associates; and (iii) an increase of approximately 30% in the number of first-time check earners with USANA. Going forward, we expect these initiatives to contribute to the growth of our worldwide customer counts.”
Net sales in Asia Pacific increased by 4.6% to $107.4 million, compared with $102.7 million for the third quarter of the prior year. This improvement was due primarily to sales growth in the Southeast Asia Pacific region, which was driven by meaningful growth in Singapore and Malaysia. Sales in the Greater China region were flat, with significant growth in Mainland China and Taiwan, offset by a sales decrease in Hong Kong.
Net sales in North America/Europe increased by 6.1% to $66.3 million, compared with $62.5 million in the prior-year period. This improvement was due primarily to sales growth in Mexico and Canada, as well as the addition of our newest market, Colombia, which generated $1.4 million in sales during its first quarter of operations. The sales growth in these markets reflected increases in both the number of Active Associates and Preferred Customers.
“The performance of our North America region reflects the momentum we are generating in Mexico, Canada and, most recently, Colombia,” continued Wentz. “Our results in Greater China were in line with our expectations, considering the worldwide policy changes that we implemented during the second quarter of this year. Our expectations for Greater China have not changed and our team continues to focus on growth in Mainland China. I am confident in the strength of our underlying business in all of our regions and believe that we have implemented the right strategies to drive long-term growth.”
The Company continued to generate significant cash from operations and ended the quarter with $115.3 million in cash and cash equivalents. For the third quarter, cash generated from operations totaled $17.3 million. During the quarter, the Company did not repurchase any shares of its common stock and ended the quarter with $13.6 million remaining under the board authorized repurchase program.
The Company provided the following updated consolidated net sales and earnings per share outlook for 2013:
Chief Financial Officer, Paul Jones, commented, “We are tightening our guidance range as we head into the final quarter of 2013 and expect USANA to once again deliver record results in 2013. Although we expect continued pressure on our operating results for the next few quarters, we are confident that we will deliver growth during this period. More importantly, we believe that the strategies that we have implemented will increase our long-term growth potential.”
USANA will hold a conference call and webcast to discuss this announcement with investors on Wednesday, October 23, 2013 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://www.usanahealthsciences.com.
USANA develops and manufactures high-quality nutritional, personal care, and weight-management products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium and Colombia. More information on USANA can be found at http://www.usanahealthsciences.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.
|USANA Health Sciences, Inc.|
|Consolidated Statements of Earnings|
|(In thousands, except per share data)|
|Quarter Ended||Nine Months Ended|
|Cost of sales||30,343||31,491||85,633||93,657|
|Selling, general and administrative||40,342||41,145||115,150||126,527|
|Earnings from operations||24,084||24,694||70,097||87,708|
|Other income (expense)||267||76||177||(33||)|
|Earnings before income taxes||24,351||24,770||70,274||87,675|
|Earnings per share - diluted||$||1.18||$||1.16||$||3.19||$||4.16|
|Weighted average shares outstanding - diluted||14,884||14,393||15,064||14,132|
|USANA Health Sciences, Inc.|
|Consolidated Balance Sheets|
|As of||As of|
|Cash and cash equivalents||$||70,839||$||115,349|
|Other current assets||25,225||35,105|
|Total current assets||132,545||196,125|
|Property and equipment, net||61,751||60,432|
|Intangible assets, net||42,085||42,078|
|Deferred income taxes||5,956||3,562|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Other current liabilities||63,804||74,474|
|Total current liabilities||70,844||82,535|
|Other long-term liabilities||938||1,127|
|Deferred income taxes||10,001||9,022|
|Total liabilities and stockholders' equity||$||267,355||$||331,333|
|USANA Health Sciences, Inc.|
|Sales by Region|
|North America / Europe||$||62,490||37.8||%||$||66,294||38.2||%|
|Southeast Asia Pacific||35,709||21.6||%||40,230||23.1||%|
|Asia Pacific Total||102,685||62.2||%||107,397||61.8||%|
|Active Associates by Region (1)|
|North America / Europe||79,000||32.6||%||82,000||33.5||%|
|Southeast Asia Pacific||58,000||24.0||%||60,000||24.5||%|
|Asia Pacific Total||163,000||67.4||%||163,000||66.5||%|
(1) Associates are independent distributors of our products who
also purchase our products for
|Active Preferred Customers by Region (2)|
|North America / Europe||52,000||81.3||%||58,000||81.7||%|
|Southeast Asia Pacific||6,000||9.4||%||8,000||11.3||%|
|Asia Pacific Total||12,000||18.8||%||13,000||18.3||%|
(2) Preferred Customers purchase our products strictly for their
personal use and are not permitted
|Streamline Health® To Announce Third Quarter Financial Results December 12, 2013 (2013/12/3)|
|Derma Sciences Reports Third Quarter Financial Results (2013/11/13)|
|Streamline Health® to Announce Second Quarter Financial Results September 9, 2013 (2013/8/26)|
|NovaCopper Announces Third Quarter Financial Results (2013/10/9)|
|ZIOPHARM Announces Third Quarter Financial Results and Updates Key Development Activities (2013/10/22)|
|Popular, Inc. Announces Third Quarter Financial Results (2013/10/23)|
|Cancer Genetics, Inc. Announces Third Quarter Financial Results (2013/11/13)|
|Ixia Announces Third Quarter Financial Results (2013/10/29)|
|SciQuest Announces Third Quarter Financial Results (2013/11/5)|
|Hampton Roads Bankshares Announces Third Quarter Financial Results (2013/11/7)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.